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Abstract 
Aim: To compare Total Laparoscopic Hysterectomy (TLH) and Total Abdominal 
Hysterectomy (TAH) with regards to surgical safety.  
Methods: Between October 2005 and June 2010, 760 patients with apparent early stage 
endometrial cancer were enrolled in a multicentre, randomized clinical trial (LACE) 
comparing outcomes following TLH or TAH. The main study end points for this analysis 
were surgical adverse events (AE), hospital length of stay, conversion from laparoscopy to 
laparotomy, including 753 patients who completed at least 6 weeks of follow-up. 
Postoperative AEs were graded according to Common Toxicity Criteria (V3), and those 
immediately life-threatening, requiring inpatient hospitalization or prolonged hospitalization, 
or resulting in persistent or significant disability/incapacity were regarded as serious AEs.  
Results: The incidence of intra-operative AEs was comparable in either group. The incidence 
of post-operative AE CTC Grade 3+ (18.6% in TAH, 12.9% in TLH, p 0.03) and serious AE 
(14.3% in TAH, 8.2% in TLH, p 0.007) was significantly higher in the TAH group compared 
to the TLH group. Mean operating time was 132 minutes and 107 minutes, and median length 
of hospital stay was 2 days and 5 days in the TLH and TAH group, respectively (p <0.0001). 
The decline of haemoglobin from baseline to day 1 postoperatively was 2 g/L less in the TLH 
group (p 0.006).  
Conclusions: Compared to TAH, TLH is associated with a significantly decreased risk of 
major surgical AEs. A laparoscopic surgical approach to early stage endometrial cancer is 
safe.  
Clinical Trial Registration: NCT00096408 
Keywords: Endometrial cancer; safety; surgery 
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Introduction 
Endometrial cancer is the most common gynecological cancer among women in developed 
countries. Worldwide, more than 300,000 women were diagnosed with uterine cancer in 2010 
and this number is projected to increase to 471,061 by 2030.(1)  Treatment is primarily 
surgical, and includes the removal of the uterus, the tubes and the ovaries with or without 
surgical staging.  
Previously we reported that patients undergoing a Total Laparoscopic Hysterectomy (TLH) 
reported significantly greater postsurgical improvement of Quality of Life (QoL) compared to 
Total Abdominal Hysterectomy (TAH) (Laparoscopic Approach to Carcinoma of the 
Endometrium trial; LACE) (2). This improvement in QoL continued to favor the laparoscopic 
approach for up to 6 months post-surgery. Two randomized clinical trials reported results on 
surgical Adverse Events (AE) (3, 4). The US Gynecologic Oncology Group  (GOG) LAP2 
showed that a laparoscopic surgical approach resulted in fewer post-operative 
moderate/severe surgical complications and shorter hospital stay than surgery through 
laparotomy (4). In contrast, the Dutch TLH study suggested that the incidence of major and 
minor surgical complications is similar in patients undergoing a TLH or TAH (3).   
The LACE trial was initiated to compare TLH and TAH with regards to QoL outcomes and 
disease-free survival in patients with apparent early-stage endometrial cancer. For the aim of 
this report, measures of surgical safety were examined. 
 
Patients and Methods 
The LACE trial commenced enrolment in 2005, was registered with clinicaltrials.gov 
(NCT00096408) and the Australian New Zealand Clinical Trials Registry 
(CTRN12606000261516), and approved by all relevant hospital and university ethics 
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committees. A detailed description of the surgical method (5) and study methodology 
including details of the two surgical approaches has been published previously (6).  
Patients were recruited through one of 20 participating tertiary gynaecological oncology 
centers in Australia, New Zealand, Hong Kong and Scotland. Women were eligible if they 
were aged 18 years or older, with histologically confirmed endometrioid adenocarcinoma of 
the endometrium of any International Federation of Gynecology and Obstetrics (FIGO) 
grade, and had an Eastern Cooperative Oncology Group (ECOG) score of less than 2. Further 
inclusion criteria included imaging studies (computed tomography (CT) of the abdomen and 
pelvis and chest radiograph or chest CT) suggesting the absence of extra-uterine disease. 
Patients were excluded from the study if any of the following criteria were met: histological 
cell-type other than endometrioid on curettage, clinically advanced disease (stage II – IV) or 
bulky lymph nodes on imaging, uterine size greater than 10 weeks of gestation, estimated life 
expectancy of less than 6 months, medically unfit for surgery, patient compliance or 
geographic proximity preventing adequate follow-up, or unfit to complete quality of life 
questionnaires. The FIGO criteria for stage (2009) were used.  
We followed a two-stage clinical trial design. During the first stage, the QoL substudy, we 
randomized 361 patients into TLH versus TAH to assess QoL. To establish the feasibility of 
enrolment and to maximize the evidence for the new procedure, a 2:1 randomization scheme 
was used for the first 180 patients, followed by 1:1 allocation for all remaining patients. 
When the trial was attractive for granting bodies offering seed funds, it allowed us to apply 
for substantial funding for stage 2 of the LACE trial evaluating the two surgical procedures in 
an equivalence trial design with respect to survival. Hence, another 580 patients were 
enrolled for a total of 760 patients (stage 2; completed enrolment in June 2010).  
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Randomization using stratified permuted blocks was carried out centrally and independent 
from other study procedures through a web-based system at the University of Queensland, 
ascertaining concealment of the next allocated treatment to study staff.  Randomization was 
stratified according to treating centre and by grade of differentiation (as taken from the 
endometrial biopsy/D&C) (2, 6).  
All surgeons on the trial had to be accredited gynaecological oncologists, had to have 
completed at least 20 TLHs and submitted video footage about a TLH, and finally had to 
have performed a TLH live in the presence of a senior accredited surgeon before being 
eligible to enroll patients into the trial. Surgeons discussed the study with the patients and 
obtained informed consent. Study staff then completed eligibility criteria and received 
notification of the allocated treatment via the web-based case report system. Blinding was not 
possible due to ethical considerations and the nature of the treatment.  
A full blood count as well as a range of blood chemistry tests was conducted at baseline 
(preoperatively) as a routine measure.After surgery, patients were assessed on a daily basis 
by their clinicians until discharge from hospital. A full blood count was repeated on the first 
day after surgery (Day 1). 
Adverse events during the first six weeks past surgery were recorded according to Common 
Toxicity Criteria (CTC) Version 3.   
Statistical considerations 
Patients with a minimum of 6 weeks of follow-up after surgery were included in this analysis. 
Analyses were based on ‘intention to treat’. Descriptive statistics were used to compare the 
incidence of three classifications of AE: a) intra-operative, b) postoperative CTC grade ≥ 3, 
and c) serious AEs, between the two treatment groups. A serious AE was defined as any 
event that results in death, is immediately life-threatening, requires inpatient hospitalization 
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or prolongation of existing hospitalization, or results in persistent or significant 
disability/incapacity. Chi-square tests were used to compare the frequency of AE distribution 
between treatment groups. T-test was used to compare the operating time and blood loss as 
well as length of hospital stay (after log transformation) between the treatment arms. No data 
were imputed.  
  
Results 
A total of 753/760 (99.1%) patients who completed at least 6 weeks of follow up were 
included in the analysis. Four patients withdrew from the trial between randomization and 
surgery and three additional patients withdrew within a week after surgery. Mean (SD) age 
was 63 (10) years at diagnosis. Of these, 349 were allocated to TAH and 404 to TLH (Table 
1). The treatment groups were balanced in terms of relevant clinical and demographic factors. 
Three hundred and seventy-one (49.3%) patients underwent lymph node dissection, 210 
(60.2%) in the TAH compared to 161 (39.9%) in the TLH groups (p<0.001).  
There were 24/404 and 26/349 readmissions in the TLH and TAH groups, respectively 
(p=0.40). A total of 51 (6.8%) patients had at least one intra-operative AE, 117 (15.5%) 
patients had at least one post-operative AE CTC grade ≥ 3, and 83 (11.0%) patients had at 
least one serious AE (Table 2). The incidence of intraoperative AE was similar between the 
treatment allocation arms (TAH 4.6%; TLH 7.4%; p 0.105). There were 12 cases of vaginal 
laceration in the TLH compared to 0 in the TAH group, resulting from a disproportion of 
uterine size and vaginal width. Patients randomized to TAH had a 44% higher incidence of 
postoperative AE CTC grade ≥ 3 (18.6% in TAH, 12.9% in TLH, p 0.03) when compared to 
those randomized to TLH. The incidence of serious AE was 74% higher in the TAH group 
compared with the TLH group (14.3% in TAH, 8.2% in TLH, p = 0.007).  Wound infection 
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or dehiscence contributed to the statistically significant differences between the treatment 
arms for post-operative AE and serious AE (Table 1). Risk factors for the development of 
surgical AEs will be presented elsewhere (Kondalsamy-Chennakesavan et al; submitted for 
publication in a companion paper). There were no deaths within 30 days from surgery in 
either treatment arm.  
Duration of surgery was 25 minutes longer in the TLH compared to the TAH arm (p <0.001), 
while the drop in hemoglobin from baseline to day 1 postoperatively was 2.3 g/L lower in the 
TLH compared to the TAH arm (p 0.006). The median length of hospital stay was 2 days in 
the TLH arm and 5 days in the TAH arm (p < 0.001) (Table 3). Table 4 describes the 
incidence of AEs stratified by treatment arm in the subgroups according to nodal dissection 
status. No significant differences in the incidence of AEs (CTC 3+) were noted between the 
treatment arms when stratified by nodal dissection status. However, serious AEs were lower 
in the TLH arm when nodal dissection was not performed.  
Treatment Crossovers: Overall, 29 conversions (3.8%) were recorded, 5 from TAH to TLH 
due to patient decision after randomization and 24 from TLH to TAH (15 for anatomical 
reasons of which 6 needed an abdominal incision to remove the uterus, 2 for technical 
reasons, and 7 due to intra-operative complications). The odds of conversion to TAH were 
1.07 (95% CI 1.02 – 1.12) with each unit increase in BMI in univariate analysis, and 1.08 
(1.03 – 1.14) when BMI was adjusted for age.  
 
Discussion 
Laparoscopic surgical approaches are becoming increasingly popular for surgical cancer 
treatment, and randomized trials such as the LACE trial are important to provide the evidence 
whether a minimally invasive surgical approach to the treatment of apparent early-stage 
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endometrial cancer is at least equivalent to open abdominal surgery. This analysis shows that 
patients allocated to TLH had a 74% decreased risk of a serious AE from their surgery when 
compared to patients allocated to TAH. Results on disease-free and overall survival are still 
pending and will be reported once follow up data collection has been completed.  
Patients in the laparoscopic arm (39.9%) were less likely to have a retroperitoneal node 
dissection than in the open arm (60.2%). While there was no data collected on the reason for 
surgeons’ decision for or against a lymphnode dissection, the decision not to proceed with a 
node dissection in laparoscopic cases was most likely based on the feasibility of a node 
dissection in obese and super-obese patients, surgeons attitude to avoid harm ,and the absence 
of a dogmatic approach to node dissection in the trial protocol. Patients’ mean body mass 
index in the present trial was 35 compared to only 30 in LAP2 (4) and the Dutch (3) trial.  
Modern evidence suggests that the gain from a pelvic and aortic node dissection is 
questionable (7,8) but the harm of a conversion to laparotomy in obese and super-obese 
women is significant (9). In a case where TAH is performed, the harm of laparotomy is 
already done and surgeons may thus have based the decision to proceed with a node 
dissection mainly on tumour (grade, depth of invasion) and patient (BMI, medical co-
morbidities) factors.  
While it could be argued that lympnode dissection rather than the surgical approach 
contributed to the difference in the AE prevalence between the two surgical arms, our results 
indicate that this is not the case. When compared to patients in the TLH group, the odds of 
patients treated with TAH to develop an AE group was consistently higher regardless of 
whether the patients had no, any, a pelvic or an aortic lymphnode dissection. However, the 
numbers within individual cells are small as the LACE trial was not powered to detect 
differences of AEs within various lymphnode dissection subgroups.   
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The results of two other randomized controlled clinical trials comparing open versus 
laparoscopic surgery for endometrial cancer were published recently. The GOG LAP2 trial 
enrolled 2616 patients with stage 1 to 4 uterine cancers of all cell types (4). All patients had 
to have a comprehensive surgical staging including a pelvic and aortic lymph node dissection 
regardless of FIGO grade and depth of invasion. Conversion to laparotomy was 25.8% in the 
laparoscopy group. The incidence of intraoperative surgical complications was 10% and 8% 
in the laparoscopic and open treatment group, respectively. Postoperatively moderate to 
severe surgical complications developed in 14% of patients in the laparoscopic group and 
21% in the open group.  
The Dutch trial enrolled 283 patients with stage 1 endometrioid adenocarcinoma of the 
endometrium or endometrial hyperplasia with atypia (3). Conversion to laparotomy was 
10.8%. Intraoperative complications developed in 2.7% (laparoscopic) and 4.3% (open) of 
patients. The incidence of major postoperative complications related to the surgical procedure 
was almost identical in both groups (14.6% and 14.9% in the laparoscopic and open group, 
respectively). In contrast to LAP2 and the present LACE trial, the outcomes of the Dutch trial 
suggested that major complication rates were similar in both the arms.  
There are key differences between the US LAP2 trial, The Dutch trial and the LACE trial that 
could explain some of the differences in outcomes. All patients recruited for the LAP2 trial 
underwent a comprehensive surgical staging including a pelvic and aortic lymph node 
dissection whereas none of the patients in the Dutch study underwent a nodal dissection. In 
the Australian LACE trial approximately half of all patients had a full surgical staging 
involving nodal dissection. The LAP2 trial enrolled patients with all histological cell-types 
and grades whereas the Dutch study enrolled patients with endometrioid cell type on 
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curettings with FIGO grades 1 or 2, including patients with endometrial hyperplasia with 
atypia. In our study, only patients with endometrioid cell type of all FIGO grades were 
included.  
A comparison of the crude incidence rates of AE reveals that the GOG LAP2 trial applied 
CTC Grade 2 criteria and reported lower incidence rates of post-operative AE (14% in 
laparoscopic vs. 21% in laparotomy) than the LACE trial, which used CTC Grade 3 criteria 
(12.9%, TLH vs. 18.6%, TAH). Similar to the Dutch study, we collected data on AE for a 
period of 6 weeks from surgery whereas collection of data on AE in the LAP2 trial was 
limited to 30 days from surgery.  
Conversions were lower in our LACE trial when compared to both these two trials. Reduced 
conversion rates in our study can potentially be attributed to the strict adherence to 
accreditation criteria of surgeons; to exclusion criteria of patients with a uterine size >10 
weeks; who had presence of extrauterine disease at diagnosis; or high-risk histological cell 
types. Moreover, patients with grade 1 or grade 2 tumors invading not more than half into the 
myometrium did not require a node dissection. Therefore, only half of patients in the LACE 
trial underwent a comprehensive surgical staging, and this may have assisted in keeping the 
conversion rate low. The lowest rates of AEs were noted in the TLH arm when a 
retroperitoneal node dissection was not performed.  
In the present study, risk factors increasing the risk of conversion to open hysterectomy 
included patient’s body mass index and patient’s age. The independent contribution of 
various risk factors for the development of major AEs will be presented elsewhere 
(Kondalsamy-Chennakesavan et al; submitted for publication).  
In summary, an open surgical approach with TAH is associated with a significantly increased 
risk of developing AEs when compared to treatment with TLH in apparent early stage 
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endometrial cancer. The risk of conversion from laparoscopic to open is acceptably low when 
the indication for lymph node dissection is individualized. This randomized trial 
prospectively confirms previous reports that a laparoscopic surgical approach is feasible, safe 
and should become the standard treatment once survival data confirmed equivalence with 
respect to patterns of recurrence, disease-free and overall survival.  
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Table 1: Patient characteristics 
  TLH 
n=404  
TAH 
n=349  
Age < 50 years n(%) 35 (8.7) 32 (9.2) 
BMI, kg/m2   
Normal (<25 kg/m2), n(%) 47 (12.1) 46 (13.6) 
Overweight (25 to <30kg/m2), n(%) 97 (25.0) 72 (21.3) 
Obesity Class I (30 to <35 kg/m2), n(%) 77 (19.8) 86 (25.4) 
Obesity Class II (35 to <40 kg/m2), n(%) 81 (20.9) 61 (18.1) 
Obesity Class III (40+ kg/m2), n(%) 86 (22.2) 73 (21.6) 
   
Charlson’s Index (mean, SD) 3.0 (1.8) 2.9 (1.8) 
   
Nodal dissection, n (%)a   
   Any 161/404 (39.9) 210/349 (60.2) 
   Pelvic 147/161 (91.3) 205/210 (97.6) 
   Aortic  11/161 (6.8)  43/210 (20.5) 
   Other (not specified) 13/161 (8.1) 16/210 (7.6) 
    
FIGO Surgical Stage, n(%)   
IA 285 (70.4) 237 (67.5) 
IB 55 (13.8) 44 (12.5) 
II 33 (8.2) 44 (12.5) 
IIIA 11 (2.7) 4 (1.1) 
IIIB 3 (0.7) 1 (0.3) 
IIIC1 11 (2.7) 11 (3.4) 
IIIC2 1 (0.2) 3 (0.8) 
IVA - 1 (0.3) 
IVB 3 (0.7) 3 (0.8) 
Otherb 2 (0.5) 1 (0.3) 
   
Grade on curettings, n(%)   
   1 258 (63.8) 220 (63.0) 
   2 119 (29.5) 106 (30.4) 
   3 27 (6.7) 23 (6.6) 
   
ECOG, n(%)   
   0 349 (86.4) 299 (85.7) 
   1 55 (13.6) 50 (14.3) 
Abbreviations: TLH = total laparoscopic hysterectomy; TAH=total abdominal hysterectomy; BMI: Body Mass 
Index; FIGO: International Federation of Gynecology and Obstetrics; ECOG: Eastern Cooperative Oncology 
Group;  a numbers do not add up to total due to overlap between the patients with pelvic, aortic or other nodal 
dissection  b found to have cervical cancer  
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Table 2: Intraoperative, postoperative and serious adverse events 
  TLH 
n=404 (%) 
TAH 
n= 349 (%) 
p-value 
Intraoperative    
Any 30 (7.4) 16 (4.6) 0.105 
Bowel injury 7 (1.7) 6 (1.7)  
Vaginal injury 12 (3.0) -  
Vascular injury 4 (1.0) 5 (1.4)  
Bladder injury 6 (1.5) 1 (0.3)  
Blood transfusion 3 (0.7) 4 (1.1)  
Ureteric injury - 2 (0.6)  
Nerve injury 1 (0.2) -  
 
Postoperative, CTCa ≥3 
   
Any 52 (12.9) 65 (18.6) 0.030 
Wound infection/dehiscence 8 (2.0) 31 (8.9)  
Pulmonary/upper respiratory 16 (4.0) 13 (3.7)  
Cardiac general 15 (3.7) 4 (1.1)  
Gastrointestinal/hepatobiliary 4 (1.0) 15 (4.3)  
Infection 12 (3.0) 7 (2.0)  
Metabolic/laboratory 7 (2.7) 9 (2.6)  
Haemorrhage/bleeding 8 (2.0) 3 (0.9)  
Blood/bone marrow 3 (0.7) 10 (2.9)  
Renal/genitourinary 4 (1.0) 5 (1.4)  
Constitutional symptoms 3 (0.7) 4 (1.1)  
Neurology 6 (1.5) 2 (0.6)  
Othersb 5 (1.2) 2 (0.6)  
Vascular 3 (0.7) 2 (0.6)  
Musculoskeletal/soft tissue 1 (0.2) 2 (0.6)  
Cardiac arrhythmia - 5 (1.4%)  
Lymphatics 1 (0.2) -  
Dermatology/Skin - 1 (0.3)  
Endocrine - 1 (0.3)  
    
Serious adverse events    
Any 33 (8.2) 50 (14.3) 0.007 
Wound infection/dehiscence 6 (1.5) 27 (7.7)  
Haemorrhage/bleeding 8 (2.0) 7 (2.0)  
Cardiac general 9 (2.2) 3 (0.9)  
Pulmonary/upper respiratory 6 (1.5) 7 (2.0)  
Infection 6 (1.5) 6 (1.7)  
Neurology 5 (1.2) 1 (0.3)  
Gastrointestinal/hepatobiliary 1 (0.2) 6 (1.7)  
Renal/genitourinary 3 (0.7) 2 (0.6)  
Surgery/Intra-operative injury 2 (0.5) 2 (0.6)  
Vascular 2 (0.5) 1 (0.3)  
Blood/bone marrow - 2 (0.6)  
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Constitutional symptoms - 2 (0.6)  
Cardiac arrhythmia 1 (0.2%) 7 (2.0)  
Endocrine/ Metabolic/laboratory - 2 (0.6)  
Othersc 1 (0.2%) 1 (0.3)  
Abbreviations: TLH = total  laparoscopic hysterectomy. TAH=total abdominal hysterectomy.            
aCommon Toxicity Criteria                                                                                                       
bIncludes return to theatre same admission, depression, anxiety, panic attack 
cIncludes return to theatre same admission  
19 
 
Table 3: Comparison of clinical factors using intention-to-treat analysis 
 
  
TLH 
(n=404) 
TAH 
(n=349) Difference 
Lower 
95% CI 
limit 
Upper 
95% CI 
limit 
p-
value 
Duration of surgery (mins), 
mean (sd) 132 (40.7) 107 (33.6) 25.6 20.3 30.9 <0.001
Drop in haemoglobin (g/dL), 
mean (sd) 17.0 (10.4) 19.3 (10.8) -2.25 -3.84 -0.66 0.006 
Log length of stay, mean (sd) 0.874 1.613 -0.740 -0.798 -0.681 <0.001
Exponentiated estimates for 
length of stay (days) 2.396 5.018 2.1 1.98 2.22   
Abbreviations: TLH = total  laparoscopic hysterectomy; TAH=total abdominal hysterectomy; CI = Confidence 
Interval          
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Table 4. Adverse Events by treatment arm and nodal dissection status 
 
 
 
  LND performed (n=371) LND not performed (n=382) 
  TLH 
(n=161) 
TAH 
(n=210) 
OR 
(TAH:TLH)
p-
value 
TLH 
(n=243) 
TAH 
(n=139) 
OR 
(TAH:TLH)
p-
value 
 n (%) n (%)   n (%) n (%)   
          
Postoperative 
CTC 3+ 
23 (14.3) 42 (20.0) 1.40 0.15 29 (11.9) 23 (16.6) 1.39 0.21 
Serious 
adverse event 
18 (11.2) 32 (15.2) 1.36 0.26 15 (6.2) 18 (13.0) 2.10 0.02 
   
Pelvic LND performed* (n=352) 
 
Pelvic LND not performed (n=401) 
  TLH 
(n=147) 
TAH 
(n=205) 
OR 
(TAH:TLH)
p-
value 
TLH 
(n=257) 
TAH 
(n=144) 
OR 
(TAH:TLH)
p-
value 
          
Postoperative 
CTC 3+ 
21 (14.3) 38 (18.5) 1.29 0.29 31 (12.1) 27 (18.8) 1.55 0.14 
Serious 
adverse event 
17 (11.6) 29 (14.1) 1.22 0.48 16 (6.2) 21 (14.6) 2.35 0.006 
   
Aortic LND performed (n=54) 
 
Aortic LND not performed (n=699) 
  TLH 
(n=11) 
TAH 
(n=43) 
OR 
(TAH:TLH)
p-
value 
TLH 
(n=393) 
TAH 
(n=306) 
OR 
(TAH:TLH)
p-
value 
          
Postoperative 
CTC 3+ 
3 (27.3) 15 (34.9) 1.28 0.63 49 (12.5) 50 (16.3) 1.30 0.15 
Serious 
adverse event 
2 (18.2) 9 (20.9) 1.15 0.84 31 (7.9) 41 (13.4) 1.70 0.02 
Abbreviations: LND: Lymph Node Dissection; TAH: total abdominal hysterectomy; TLH: total  laparoscopic 
hysterectomy  
 
 
 
 
 
